Access to anti-retroviral drugs, female in Albania

Albania: Access to anti-retroviral drugs, female was 64.0% in 2024. ◆ Volatile

Latest (2024)
64.0%
Change on year
up 4.9%
World rank
95th
of 141 countries
All-time high
64.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Albania, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 5 %2005: 11 %2006: 13 %2007: 12 %2008: 17 %2009: 18 %2010: 20 %2011: 23 %2012: 31 %2013: 43 %2014: 43 %2015: 48 %2016: 50 %2017: 49 %2018: 52 %2019: 53 %2020: 58 %2021: 61 %2022: 63 %2023: 61 %2024: 64 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Albania stood at 64.0%. That is the highest value across all 25 years on record.

That represents a change of up 4.9% on the previous year and up 48.8% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Albania peaked at 64.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Albania 95th out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Albania, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Albania, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 5.0%
2005 11.0% +120.0%
2006 13.0% +18.2%
2007 12.0% -7.7%
2008 17.0% +41.7%
2009 18.0% +5.9%
2010 20.0% +11.1%
2011 23.0% +15.0%
2012 31.0% +34.8%
2013 43.0% +38.7%
2014 43.0% +0.0%
2015 48.0% +11.6%
2016 50.0% +4.2%
2017 49.0% -2.0%
2018 52.0% +6.1%
2019 53.0% +1.9%
2020 58.0% +9.4%
2021 61.0% +5.2%
2022 63.0% +3.3%
2023 61.0% -3.2%
2024 64.0% +4.9%

Averages by decade

DecadeAverage LowestHighest Years
2000s 7.6% 0.0% 18.0% 10
2010s 41.2% 20.0% 53.0% 10
2020s 61.4% 58.0% 64.0% 5

Countries ranked near Albania

  1. 96 Chile 63.0% compare
  2. 96 Gabon 63.0% compare
  3. 96 Slovakia 63.0% compare

See the full ranking of 160 places →

More gender data for Albania

All data for Albania →

Frequently asked questions

What is access to anti-retroviral drugs, female in Albania?
Access to anti-retroviral drugs, female in Albania was 64.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Albania?
The highest recorded value was 64.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Albania?
The lowest recorded value was 0.0% in 2000.
How does Albania rank for access to anti-retroviral drugs, female?
Albania ranks 95th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Albania?
Over the last ten years it is up 48.8%. The long-run trend across the full record is volatile.
Where does this Albania data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Albania. Statizoid, drawing on UNAIDS estimates. Retrieved 12 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/albania/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/albania/">Access to anti-retroviral drugs, female in Albania</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.